January 31, 2023
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
January 5, 2023
Athira Pharma Provides 2023 Pipeline Outlook
December 21, 2022
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
December 5, 2022
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
December 1, 2022
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
November 29, 2022
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
November 28, 2022
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
November 21, 2022
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 16, 2022
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
November 10, 2022
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Displaying 11 - 20 of 104